Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 26
- Registration Number
- NCT01879228
- Locations
- 🇺🇸
Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 38
- Registration Number
- NCT01859793
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 292
- Registration Number
- NCT01845831
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 642
- Registration Number
- NCT01841697
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 96
- Registration Number
- NCT01834274
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01824264
Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users
- Conditions
- Interventions
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Anna Cruceta
- Target Recruit Count
- 13
- Registration Number
- NCT01785043
- Locations
- 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 70
- Registration Number
- NCT01744236
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Sitagliptin in Type I Diabetic Patients
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- University at Buffalo
- Registration Number
- NCT01741103
- Locations
- 🇺🇸
115 Flint Road, Williamsville, New York, United States
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Nemours Children's Clinic
- Target Recruit Count
- 6
- Registration Number
- NCT01721382
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.